Se încarcă compania
Just reported
Q3 2026 results
From Pacific Biosciences of California's results release of 4 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
40,6M USD
+5,5 % y/y
+4,0 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,12 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-37M USD
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue155M USD – 160M USD-1,6 % y/y Lowered -1,6 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Pacific Biosciences of California is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc130B USDA+
SYKStryker Corp.121,3B USDA+
EWEdwards Lifesciences Corporation60,8B USDA+
GEHCGE Healthcare Technologies Inc.37,4B USDA
GKOSGlaukos Corp14,6B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Situațiile financiare complete →
Construit din raportările proprii ale Pacific Biosciences of California, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
